ClinicalTrials.gg
TerminatedNCT03108495Updated Sep 25, 2026Results posted

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

A Phase 2 interventional study of LN-145 and LN-145 + pembrolizumab in Cervical Carcinoma, sponsored by Iovance Biotherapeutics, Inc.. Terminated at 43 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Iovance Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.
Updated Sep 25, 2026Posted results revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 145 open to participants now, 219 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Enrollment
186th of 678
210 · median 71
Started
2017
with 25 others
Phase 2
165 of 834
25 open now
Registered
429th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 186th largest by enrollment of the 678 interventional ones that give a count, is one of 26 that started in 2017, is one of 165 in phase 2, and was the 429th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

145 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

140 more — sign in →

All 145 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.

Read the detailed description

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves participants receiving a non-myeloablative lymphodepletion (NMA-LD) preparative regimen, followed by infusion of autologous TIL, with or without pembrolizumab, followed by the administration of a regimen of IL-2.

03

Conditions studied

  • Cervical Carcinoma

Keywords

  • LN-145
  • Cell Therapy
  • Autologous Adoptive Cell Transfer
  • Autologous Adoptive Cell Therapy
  • Cellular Immuno-therapy
  • Tumor Infiltrating Lymphocytes
  • TIL
  • IL-2
  • Pembrolizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for the study, participants must meet ALL of the following criteria prior to participation:

  1. Must be ≥ 18 years of age at the time of consent. Enrollment of participants > 70 years of age may be allowed after consultation with the Medical Monitor.
  2. Must have recurrent, , or persistent squamous cell carcinoma (SCC), adenosquamous carcinoma (ASC), or adenocarcinoma (AC) of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy.
  3. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post-resection to generate TIL; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)
  4. At least one measurable target lesion, as defined by v1.1.
  5. Cohort 1 and Cohort 2: Progression during or following at least one, but no more than three, prior systemic chemotherapeutic treatments for recurrent, metastatic, or persistent cervical carcinoma

    • A is defined as any chemotherapy or multiple-agent chemotherapy regimen that was administered for recurrent, metastatic, or persistent SCC, ASC, or AC of the cervix.
    • A bevacizumab and chemotherapy combination is encouraged as a prior line of treatment.
    • Neither chemoradiation, nor chemotherapy in the or adjuvant settings are considered as a prior line of systemic therapy.

    Cohort 2: Must also have previously received treatment with a (ie, PD-1, PD-L1]) in the setting of recurrent, metastatic, or persistent disease either as monotherapy or in combination (eg, in combination with chemotherapy or another immune agent)

    Cohort 3 (United States only): Must have not received any therapies other than prior chemoradiation or surgery for loco-regional disease

  6. Any prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted agents, and immunologic agents must be discontinued at least 28 days prior to tumor resection.
  7. Have an (ECOG) performance status of 0 or 1
  8. Must have adequate organ function.
  9. Participant has no evidence of any active viral, bacterial, or fungal infection requiring ongoing systemic treatment. Participants must be seronegative for the (HIV). Participants with acute or chronic hepatitis infections may be enrolled if the viral load by nucleic acid amplification test (NAAT) is undetectable with/without active treatment
  10. Participants of must be willing to take the appropriate precaution to avoid pregnancy for the duration of the study and practice an approved, highly effective method of during treatment and for 12 months after receiving the last protocol-related therapy.
  11. Prior to study Enrollment (tumor resection), participant must have documentation of radiological disease progression after the most recent therapy

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria are not eligible for participation in this study:

  1. Participants who have received an organ allograft or prior cell transfer therapy except for prior LN-145 therapy in the setting of re-treatment only.
  2. Participants who require ongoing systemic therapy (> 10 mg/day of prednisone or other steroid equivalent dose).
  3. Participants who currently have prior therapy-related toxicities Grade > 1 according to National Cancer Institute (NCI) (CTCAE) v5.0; except for peripheral neuropathy, alopecia, or vitiligo prior to Enrollment (tumor resection).
  4. . Participants who have a history of to any component or of LN-145 or other study drugs:

    • NMA-LD preparative regimen (cyclophosphamide, mesna, and fludarabine)
  5. Participants who have active systemic infections, coagulation disorders, or other active major medical illness(es) of the cardiovascular, respiratory, or immune system, including evidence in the medical history of urinary tract obstruction, a positive cardiac stress test, myocardial infarction, cardiac arrhythmia, obstructive or restrictive pulmonary disease, or other conditions that in the opinion of the Investigator would increase the risk of participation.
  6. Participants with symptomatic and/or untreated (of any size and any number)

    • Participants with definitively treated brain metastases may be considered for Enrollment, and must be stable for ≥ 14 days prior to beginning the NMA-LD preparative regimen
  7. Participants who have any form of primary immunodeficiency (such as severe combined immunodeficiency [SCID] or acquired immunodeficiency syndrome [AIDS])
  8. Participants who have a diagnosis of end-stage renal disorder requiring hemodialysis
  9. Participants who have a (LVEF) \< 45% or who are (NYHA) Class 2 or higher.
  10. Participants who have a documented (FEV1) of ≤ 60%
  11. Participants who have had another primary within the previous 3 years (except for curatively treated localized malignancy that has not required treatment for > 1 year, and in the judgement of the Investigator, does not pose a significant risk of recurrence including, but not limited to, non-melanoma skin cancer or bladder cancer)
  12. Participants who are of the following protected classes will be excluded, including:

    • Pregnant, parturient, or breastfeeding women
    • Persons who are hospitalized without consent or those deprived of liberty because of a judiciary or administrative decision
    • Participants with a legal protection measure or a person who cannot express his/her consent
    • Participants in emergency situations who cannot consent to the study
  13. Participants who have received a live or attenuated vaccine within 28 days prior to beginning the NMA-LD preparative regimen
  14. Participants whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this study
  15. Cohort 1 and Cohort 3: Participants who have received prior treatment with immunotherapy (eg, , PD-L1, or anti-cytotoxic T lymphocyte-associated antigen-4 [CTLA-4] antibodies)
  16. Participants who have Grade ≥ 2 hemorrhage within 14 days prior to Enrollment (tumor resection)
  17. Cohort 3: Participants may not have active or prior documented or inflammatory disorders (including pneumonitis, inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Cohort 1 LN-145 monotherapy

    LN-145 monotherapy in participants who have progressed during or following systemic therapy; this cohort is no longer open for enrollment.

    Biological: LN-145

  • Experimental
    Cohort 2 LN-145 monotherapy

    LN-145 monotherapy in participants who have previously received a PD-1/PD-L1 checkpoint inhibitor either as monotherapy or combination therapy.

    Biological: LN-145

  • Experimental
    Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only

    LN-145 in combination with pembrolizumab in participants who have not received any therapies other than prior chemoradiation or surgery for loco-regional disease.

    Biological: LN-145 + pembrolizumab

  • Experimental
    Cohort 4 - Previously Enrolled Cohort

    LN-145 monotherapy in previously enrolled participants who do not meet requirements for inclusion in the other study cohorts; this cohort is not open for enrollment.

    Biological: LN-145

  • Experimental
    Cohort 5 Retreatment Cohort

    LN-145 monotherapy as a re-treatment.

    Biological: LN-145

Interventions

  • BiologicalLN-145

    Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

    A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.

    Also known as: TIL, autologous tumor infiltrating lymphocytes

  • BiologicalLN-145 + pembrolizumab

    Drug pages: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145 · Pembrolizumab

    A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.

    Also known as: TIL, autologous tumor infiltrating lymphocytes; pembrolizumab (anti-PD-1 immunotherapy)

06

What researchers measure

Primary outcomes

  1. Cohort 1 and 2: Objective Response Rate

    To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 60 months

  2. Cohort 3: Number of Participants With Adverse Events

    To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

    Time frame: Up to 60 months

  3. Cohort 4: Number of Participants With Adverse Events

    To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

    Time frame: Up to 60 months

  4. Cohort 4: Efficacy/Objective Response Rate

    To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 60 months

  5. Cohort 5: Number of Participants With Adverse Events

    To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

    Time frame: Up to 60 months

  6. Cohort 5: Efficacy/Objective Response Rate

    To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 60 months

Secondary outcomes

  1. Cohort 1 and 2: Duration of Response

    To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.

    Time frame: Up to 60 months

  2. Cohort 1 and 2: Disease Control Rate

    To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.

    Time frame: Up to 60 months

  3. Cohort 1 and 2: Progression-Free Survival

    To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 60 months

  4. Cohort 1 and 2: Overall Survival

    To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma

    Time frame: Up to 60 months

  5. Cohort 1 and 2: Number of Participants With Adverse Events

    To characterize the safety profile of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

    Time frame: Up to 60 months

  6. Cohort 3: Objective Response Rate

    To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 60 months

  7. Cohort 3: Duration of Response

    To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.

    Time frame: Up to 60 months

  8. Cohort 3: Disease Control Rate

    To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.

    Time frame: Up to 60 months

  9. Cohort 3: Progression-Free Survival

    To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: Up to 60 months

  10. Cohort 3: Overall Survival

    To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma.

    Time frame: Up to 60 months

07

Results

Posted Jul 31, 2026

Participant flow

Initial Treatment
Participant flow — Initial Treatment
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started1006232160
Participants infused with til744226100
Completed70110
Not completed936231150
Withdrew: Did not receive til2620660
Withdrew: Death63341790
Withdrew: Lost to follow-up23000
Withdrew: Withdrawal by subject24100
Withdrew: Study terminated by sponsor01700
Retreatment
Participant flow — Retreatment
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started00006
Participants infused with til00002
Completed00000
Not completed00006
Withdrew: Did not receive til00004
Withdrew: Death00002

Outcome measures

PrimaryCohort 1 and 2: Objective Response Rate

To evaluate the efficacy of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 1 and 2: Objective Response Rate
ParticipantsCohort 1Cohort 2
Cohort 1 and 2: Objective Response Rate155
PrimaryCohort 3: Number of Participants With Adverse Events

To characterize the safety profile of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 3: Number of Participants With Adverse Events
ParticipantsCohort 3
Cohort 3: Number of Participants With Adverse Events26
PrimaryCohort 4: Number of Participants With Adverse Events

To explore the safety profile of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 4: Number of Participants With Adverse Events
ParticipantsCohort 4
Cohort 4: Number of Participants With Adverse Events10
PrimaryCohort 4: Efficacy/Objective Response Rate

To explore the efficacy of LN-145 in previously enrolled participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 4: Efficacy/Objective Response Rate
ParticipantsCohort 4
Cohort 4: Efficacy/Objective Response Rate2
PrimaryCohort 5: Number of Participants With Adverse Events

To explore the safety profile of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 5: Number of Participants With Adverse Events
ParticipantsCohort 5
Cohort 5: Number of Participants With Adverse Events2
PrimaryCohort 5: Efficacy/Objective Response Rate

To explore the efficacy of LN-145 in re-treated participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 5: Efficacy/Objective Response Rate
ParticipantsCohort 5
Cohort 5: Efficacy/Objective Response Rate0
SecondaryCohort 1 and 2: Duration of Response

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 1 and 2: Duration of Response
monthsCohort 1Cohort 2
Cohort 1 and 2: Duration of Response6.8 (2.5 to NA)6.7 (4.2 to NA)
SecondaryCohort 1 and 2: Disease Control Rate

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 1 and 2: Disease Control Rate
ParticipantsCohort 1Cohort 2
Cohort 1 and 2: Disease Control Rate4323
SecondaryCohort 1 and 2: Progression-Free Survival

To evaluate the efficacy parameters of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 1 and 2: Progression-Free Survival
monthsCohort 1Cohort 2
Cohort 1 and 2: Progression-Free Survival2.8 (2.3 to 4.1)2.8 (1.5 to 2.9)
SecondaryCohort 1 and 2: Overall Survival

To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 1 and 2: Overall Survival
monthsCohort 1Cohort 2
Cohort 1 and 2: Overall Survival8.8 (6.7 to 11.4)8.2 (4.0 to 10.3)
SecondaryCohort 1 and 2: Number of Participants With Adverse Events

To characterize the safety profile of LN-145 in participants with recurrent, metastatic, or persistent cervical carcinoma as assessed by number of participants with adverse events.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 1 and 2: Number of Participants With Adverse Events
ParticipantsCohort 1Cohort 2
Cohort 1 and 2: Number of Participants With Adverse Events7442
SecondaryCohort 3: Objective Response Rate

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 3: Objective Response Rate
ParticipantsCohort 3
Cohort 3: Objective Response Rate13
SecondaryCohort 3: Duration of Response

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions. DOR is measured from the first time response (PR/CR) criteria are met until the first date of progression, or the participant expires.

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 3: Duration of Response
monthsCohort 3
Cohort 3: Duration of ResponseNA (4.4 to NA)
SecondaryCohort 3: Disease Control Rate

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1) for target lesions based on imaging: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), \<20% increase nadir SLD (sum of longest diameter of target lesions). DCR is defined as the proportion of participants who have CR or PR or SD per RECIST v1.1.

Time frame:
Up to 60 months
Reported as:
Count of participants · Participants
Cohort 3: Disease Control Rate
ParticipantsCohort 3
Cohort 3: Disease Control Rate23
SecondaryCohort 3: Progression-Free Survival

To evaluate the efficacy of LN-145 in combination with pembrolizumab in participants with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the Investigator per Response Evaluation Criteria In Solid Tumors (RECIST v1.1). Progression is defined using RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 3: Progression-Free Survival
monthsCohort 3
Cohort 3: Progression-Free Survival6.2 (3.3 to NA)
SecondaryCohort 3: Overall Survival

To evaluate overall survival (OS) in participants with recurrent, metastatic, or persistent cervical carcinoma.

Time frame:
Up to 60 months
Reported as:
Median · months
Cohort 3: Overall Survival
monthsCohort 3
Cohort 3: Overall Survival27.7 (15.2 to 41.6)

Adverse events

Collected over From enrollment to end of follow-up (up to 60 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 163/74 (85.1%)31/74 (41.9%)74/74 (100%)
Cohort 234/42 (81%)20/42 (47.6%)42/42 (100%)
Cohort 317/26 (65.4%)18/26 (69.2%)26/26 (100%)
Cohort 49/10 (90%)7/10 (70%)10/10 (100%)
Cohort 52/2 (100%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 88
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
NauseaGastrointestinal disorders0/740/421/260/101/2
VomitingGastrointestinal disorders1/740/422/261/101/2
DehydrationMetabolism and nutrition disorders1/740/420/260/101/2
Acute kidney injuryRenal and urinary disorders4/746/422/260/100/2
Respiratory failureRespiratory, thoracic and mediastinal disorders0/741/423/260/100/2
ThrombocytopeniaBlood and lymphatic system disorders4/743/420/261/100/2
Acute myocardial infarctionCardiac disorders0/740/420/261/100/2
Cardiac failure congestiveCardiac disorders0/740/420/261/100/2
Ventricular fibrillationCardiac disorders0/740/420/261/100/2
Systemic inflammatory response syndromeGeneral disorders0/740/420/261/100/2
Most frequent other events
Showing 10 of 398
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
ChillsGeneral disorders45/7425/4223/265/100/2
NauseaGastrointestinal disorders19/743/4222/261/100/2
AnaemiaBlood and lymphatic system disorders49/7424/4220/267/101/2
ThrombocytopeniaBlood and lymphatic system disorders39/7426/4215/267/101/2
VomitingGastrointestinal disorders22/749/4218/263/101/2
FatigueGeneral disorders16/745/4217/262/100/2
NeutropeniaBlood and lymphatic system disorders26/747/4214/266/100/2
PyrexiaGeneral disorders41/7413/4214/266/100/2
ConstipationGastrointestinal disorders9/745/4215/260/101/2
HypoxiaRespiratory, thoracic and mediastinal disorders20/746/4215/262/100/2

Baseline characteristics

The Safety Analysis Set is defined as participants who received TIL. Cohort 5 participants had progressed following the initial TIL treatment in Cohorts 1 or 2, and then were retreated with a second TIL treatment. Data are captured for retreatment in Cohort 5.

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Initial Treatment — <=18 years010001
Initial Treatment — Between 18 and 65 years693723100139
Initial Treatment — >=65 years5430012
Retreatment — <=18 years000000
Retreatment — Between 18 and 65 years000022
Retreatment — >=65 years000000
Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Initial Treatment44 (24 to 72)46.5 (18 to 72)46.5 (31 to 73)46.5 (38 to 61)—45 (18 to 73)
Retreatment————49.5 (43 to 56)49.5 (43 to 56)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Initial Treatment — Female744226100152
Initial Treatment — Male000000
Retreatment — Female————22
Retreatment — Male————00
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Initial Treatment — Hispanic or Latino5741017
Initial Treatment — Not Hispanic or Latino60352270124
Initial Treatment — Unknown or Not Reported9002011
Retreatment — Hispanic or Latino000000
Retreatment — Not Hispanic or Latino000022
Retreatment — Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Initial Treatment — American Indian or Alaska Native000000
Initial Treatment — Asian423009
Initial Treatment — Native Hawaiian or Other Pacific Islander000000
Initial Treatment — Black or African American230005
Initial Treatment — White58332390123
Initial Treatment — More than one race000000
Initial Treatment — Unknown or Not Reported10401015
Retreatment — American Indian or Alaska Native000000
Retreatment — Asian000000
Retreatment — Native Hawaiian or Other Pacific Islander000000
Retreatment — Black or African American000000
Retreatment — White000022
Retreatment — More than one race000000
Retreatment — Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Netherlands800008
United States40352690110
United Kingdom700007
France400105
Switzerland310004
Germany610007
Spain6500011
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
United States————11
Switzerland————11
08

Study locations

43 sites
  • St. Joseph's Hospital and Medical Center Center For Women's Health
    Phoenix, Arizona 85013, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of California San Diego
    San Diego, California 92093, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Florida Health Cancer Center
    Orlando, Florida 32806, United States
  • University of South Florida H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Augusta University
    Augusta, Georgia 30912-0003, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • LSU Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287-0013, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Rutgers University
    Newark, New Jersey 07103, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Allegheny Health
    Pittsburgh, Pennsylvania 15224, United States
  • UPMC Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Avera Medical Group Oncology
    Sioux Falls, South Dakota 57105, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53225, United States
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Auvergne-Rhône-Alpes 69495, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Gustave Roussy Cancer Campus
    Villejuif, 94805, France
  • Universitätsklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Saxony 01307, Germany
  • Istituto Europeo di Oncologia
    Miano, Milano 20141, Italy
  • Academisch Medisch Centrum
    Amsterdam, AZ 1105, Netherlands
  • Clínica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
  • Hospital Universitari Vall d'Hebrón
    Barcelona, 08035, Spain
  • Institut Català d'Oncologia
    Barcelona, 08908, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Inselspital
    Bern, CH-3010, Switzerland
  • Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie
    Lausanne, Switzerland
  • Bristol Haematology and Oncology Centre
    Bristol, England BS2 8ED, United Kingdom
  • Sarah Cannon Research Institute London
    London, England W1G 6AD, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, England W1G 6BW, United Kingdom
  • NHS Greater Glasgow and Clyde
    Glasgow, Scotland G12 0YN, United Kingdom
  • Guy's & St.Thomas NHS Foundation Trust
    London, SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Aug 2025, 98 months.

Results were first posted in Jul 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2017
First posted
Apr 11, 2017
StartActual
Jun 22, 2017
Primary completionActual
Aug 22, 2025
CompletionActual
Aug 22, 2025
Results first posted
Jul 31, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Sep 25, 2026
Primary outcomes
3 edited, 3 description edited
What changed in the outcomes
  • EditedCohort 3: Number of Participants With Adverse EventsTime frame: Up to 60 months
  • EditedCohort 4: Number of Participants With Adverse EventsTime frame: Up to 60 months
  • EditedCohort 5: Number of Participants With Adverse EventsTime frame: Up to 60 months
  • DescriptionCohort 1 and 2: Objective Response Rate: how it is measured was reworded
  • DescriptionCohort 4: Efficacy/Objective Response Rate: how it is measured was reworded
  • DescriptionCohort 5: Efficacy/Objective Response Rate: how it is measured was reworded
Sep 25, 2026
Secondary outcomes
1 edited, 7 description edited
What changed in the outcomes
  • EditedCohort 1 and 2: Number of Participants With Adverse EventsTime frame: Up to 60 months
  • DescriptionCohort 1 and 2: Disease Control Rate: how it is measured was reworded
  • DescriptionCohort 1 and 2: Duration of Response: how it is measured was reworded
  • DescriptionCohort 1 and 2: Progression-Free Survival: how it is measured was reworded
  • DescriptionCohort 3: Disease Control Rate: how it is measured was reworded
  • DescriptionCohort 3: Duration of Response: how it is measured was reworded
  • DescriptionCohort 3: Objective Response Rate: how it is measured was reworded
  • DescriptionCohort 3: Progression-Free Survival: how it is measured was reworded
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Posted results revised
    Primary outcomes 3 edited, 3 description edited
    What changed in the outcomes
    • EditedCohort 3: Number of Participants With Adverse EventsTime frame: Up to 60 months
    • EditedCohort 4: Number of Participants With Adverse EventsTime frame: Up to 60 months
    • EditedCohort 5: Number of Participants With Adverse EventsTime frame: Up to 60 months
    • DescriptionCohort 1 and 2: Objective Response Rate: how it is measured was reworded
    • DescriptionCohort 4: Efficacy/Objective Response Rate: how it is measured was reworded
    • DescriptionCohort 5: Efficacy/Objective Response Rate: how it is measured was reworded
    Secondary outcomes 1 edited, 7 description edited
    What changed in the outcomes
    • EditedCohort 1 and 2: Number of Participants With Adverse EventsTime frame: Up to 60 months
    • DescriptionCohort 1 and 2: Disease Control Rate: how it is measured was reworded
    • DescriptionCohort 1 and 2: Duration of Response: how it is measured was reworded
    • DescriptionCohort 1 and 2: Progression-Free Survival: how it is measured was reworded
    • DescriptionCohort 3: Disease Control Rate: how it is measured was reworded
    • DescriptionCohort 3: Duration of Response: how it is measured was reworded
    • DescriptionCohort 3: Objective Response Rate: how it is measured was reworded
    • DescriptionCohort 3: Progression-Free Survival: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03108495
Lead sponsor
Iovance Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 11, 2017
Start date
Jun 22, 2017
Primary completion
Aug 22, 2025
Completion
Aug 22, 2025
Results posted
Jul 31, 2026
Last update
Sep 25, 2026

Study contacts

Iovance Medical Monitor
study director · Iovance Biotherapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145 · Pembrolizumab

Start the discussion